Vertex   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Boston MA United States (1989)
Status: Acquired by Henry Schein, Inc (1995) → now AbbVie (2019)

Organization Overview

First Clinical Trial
1998
NCT00003847
First Marketed Drug
2011
telaprevir (incivek)
First NDA Approval
2011
telaprevir (incivek)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Veratex | Vertex Pharmaceutical Incorporated | Vertex Pharmaceuticals Incorporated | VERTEX PHARMS | VERTEX PHARMS INC